Novocure (NASDAQ:NVCR) is a global oncology company dedicated to developing a novel platform technology, Tumor Treating Fields, to create therapies for various types of cancer. This technology uses electric fields to disrupt cancer cell division, potentially improving survival for patients. Novocure's operations span research, clinical development, and the commercialization of its products worldwide, aiming to transform cancer treatment through its innovative approach. Its flagship project involves the treatment of glioblastoma, a type of brain cancer, but the company is also exploring applications in other solid tumor cancers. Novocure's objectives focus on expanding the understanding and efficacy of Tumor Treating Fields, investing in clinical trials to explore new indications, and enhancing patient access to its treatments.